Abstract

Background: Colorectal cancer is the third most commonly diagnosed cancer in the world. Primary signet-ring cell carcinoma of the colon and rectum (PSRCCR) is a rare form of adenocarcinoma, with a reported incidence of less than 1%. Because symptoms of PSRCCR often develop late, it usually has a poor prognosis. Case Presentation: A 44-yearold male presented to his general practitioner with complaints of inadequate evacuation of stool, abdominal bloating and irregular bowel movements in the last 6 months and bleeding per rectum in the past 2 weeks. Colonoscopy showed growth in the rectum; hence, a biopsy and magnetic resonance imaging (MRI) of the pelvis were done. Discussion: The patient received short course chemotherapy followed by low anterior resection with transverse loop colostomy. Out of 17 resected mesorectal lymph nodes, 7 nodes were positive. Due to the patient's young age and having locally advanced cancer with aggressive histology, adjuvant chemotherapy was started with intravenous (IV) oxaliplatin and oral capecitabine to prevent recurrence and improve overall survival. Patient completed 6 cycles of adjuvant therapy, after which end-to-end anastomosis was done, and the patient remained disease-free. Conclusion: Patients with locally advanced growth of rectal signet-ring cell carcinoma (SRCC) should be offered preoperative short-course radiotherapy with curative intent. Though the patient's cancer was in the T3N2b stage, he responded well to treatment. The chemotherapy nurse plays a significant role to ensure patients have the basic knowledge necessary to decide about treatment options.

Keywords: Colorectal adenocarcinoma · Signet-ring cell carcinoma · Short course radiation therapy · Adjuvant chemotherapy · Low anterior resection

References

  1. 1.National Cancer Institute. Rectal cancer treatment (PDQ)–Health professional version. 2016. https://www.cancer.gov/ types/colorectal/hp/rectal-treatment-pdq
  2. 2.American Cancer Society: Cancer facts and figures 2016. http://www.cancer. org/acs/groups/content/@research/ documents/document/acspc-047079.pdf
  3. 3.Park PY, Goldin T, Chang J, Markman M, Kundranda MN. Signet-ring cell carcinoma of the colon: A case report and review of the literature. Case Rep Oncol 2015;8:466-471. https://www.karger. com/Article/Pdf/441772.
  4. 4.American Cancer Society. Colorectal cancer. 2016. http://www.cancer. org/cancer/colonandrectumcancer/ detailedguide/colorectal-cancer-riskfactors.
  5. 5.Kang H, O’Connell JB, Maggard MA, Sack J, Ko CY. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum 2005;48:1161-1168.
  6. 6.Belli S, Aytac HO, Karagulle E, Yabanoglu H, Kayaselcuk F, Yildirim S. Outcomes of surgical treatment of primary signet ring cell carcinoma of the colon and rectum: 22 cases reviewed with literature. IntSurg 2014;99:691-698.
  7. 7.Lee HS, Soh JS, Lee S, Bae JH, Kim KJ, Ye BD,, et al. Clinical features and prognosis of resectableprimary colorectal signet-ring cell carcinoma.Intest Res 2015; 13(4): 332-338 http://dx.doi. org/10.5217/ir.2015.13.4.332 doi:10.5217/ir.2015.13.4.332
  8. 8.Gopalan V, Smith RA, Ho YH, Lam AK. Signet-ring cell carcinoma of colorectum – current perspectives and molecular biology. Int J Colorectal Dis 2011;26:127- 133
  9. 9.Ogino S1, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G. , et al: Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006;19:59-68.
  10. 10.Glynne-Jones R, Tan D, Moran BJ, Goh V. How to select for preoperative shortcourse radiotherapy, while considering long-course chemoradiotherapy or immediate surgery, and who benefits? Eur Oncol &Haematol 2014;10(1):17-24. http://www.touchoncology.com/articles/ how-select-preoperative-short-courseradiotherapy-while-considering-long- 72 72 Majmaah Journal of Health Sciences, Vol. 4, issue 2, November 2016 - Safar 1438 MajedAlamri and Helen Cecily: Management of Signet-ring Cell Caricoma of the Rectum:ACase Study 72 course.
  11. 11.Hong TS, Mamon H. Short-course versus standard chemoradiation in T3 rectal cancer. Oncologist 2011 May; 16(5): 717-
  12. 12.https://www.ncbi.nlm.nih.gov/pmc/ articles/PMC3228203/.
  13. 13.Hugen N, Verhoeven RH, Lemmens VE, van Aart CJ, Elferink MA, Radema SA, et al: Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. Int J Cancer 2015;136:333-339.
  14. 14.Hong TS Ryan DP. Adjuvant chemotherapy for locally advanced rectal cancer: Is it a given? J Clin Oncol 2015. http://jco.ascopubs.org/cgi/doi/10.1200/ JCO.2015.60.8554.
  15. 15.http://wps.prenhall.com/wps/media/ objects/737/755395/radiation_therapy. pdf
  16. 16.Roe, H, Lennan, E. Role of nurses in the assessment and management of chemotherapy-related side effects in cancer patients. DovePress 2014; 4: 103-115. https://www.dovepress.com/ role-of-nurses-in-the-assessment-andmanagement-of-chemotherapy-relatepeer-reviewed-fulltext-article-NRR.
Majmaah Journal of Health Sciences · eISSN 1658-8223 · Majmaah University · open access